NLS Pharmaceutics (NLSP)

• Market cap: $5.47M
• 1 day: -15.32%
• 5 days: -34.38%
• 1 month: -57.14%
• 3 months: -48.02%
• 6 months: -28.57%
• Year to date: -51.83%
• 1 year: -74.45%
• 5 years: -99.09%
• 10 years: -99.09%
• Sector: Healthcare
• Industry: Biotechnology

About: NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

Employees: 1